[go: up one dir, main page]

WO1995015293A1 - Oxyde de calcium pulverulent ultrafin, sa preparation et son utilisation - Google Patents

Oxyde de calcium pulverulent ultrafin, sa preparation et son utilisation Download PDF

Info

Publication number
WO1995015293A1
WO1995015293A1 PCT/CN1994/000097 CN9400097W WO9515293A1 WO 1995015293 A1 WO1995015293 A1 WO 1995015293A1 CN 9400097 W CN9400097 W CN 9400097W WO 9515293 A1 WO9515293 A1 WO 9515293A1
Authority
WO
WIPO (PCT)
Prior art keywords
calcium
particle size
calcium oxide
oxide powder
ultra
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN1994/000097
Other languages
English (en)
Chinese (zh)
Inventor
Zhifang Chai
Yuanji Zhang
Xueying Mao
Hong Fang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BEIJING SAN-XI CHEMICAL NEW TECHNOLOGY Co
Original Assignee
BEIJING SAN-XI CHEMICAL NEW TECHNOLOGY Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BEIJING SAN-XI CHEMICAL NEW TECHNOLOGY Co filed Critical BEIJING SAN-XI CHEMICAL NEW TECHNOLOGY Co
Priority to AU11048/95A priority Critical patent/AU1104895A/en
Publication of WO1995015293A1 publication Critical patent/WO1995015293A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01F—COMPOUNDS OF THE METALS BERYLLIUM, MAGNESIUM, ALUMINIUM, CALCIUM, STRONTIUM, BARIUM, RADIUM, THORIUM, OR OF THE RARE-EARTH METALS
    • C01F11/00—Compounds of calcium, strontium, or barium
    • C01F11/02—Oxides or hydroxides
    • C01F11/04—Oxides or hydroxides by thermal decomposition
    • C01F11/06—Oxides or hydroxides by thermal decomposition of carbonates
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
    • C01P2004/00—Particle morphology
    • C01P2004/51—Particles with a specific particle size distribution
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
    • C01P2004/00—Particle morphology
    • C01P2004/60—Particles characterised by their size
    • C01P2004/62—Submicrometer sized, i.e. from 0.1-1 micrometer
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
    • C01P2004/00—Particle morphology
    • C01P2004/60—Particles characterised by their size
    • C01P2004/64—Nanometer sized, i.e. from 1-100 nanometer

Definitions

  • the invention relates to an ultrafine calcium oxide powder and a preparation method thereof, and to a composition of ultrafine particle size (nanoscale) calcium oxide. Background of the invention
  • Calcium deficiency can cause a variety of diseases: Children with calcium deficiency can develop rickets, and are susceptible to colds, night crying, irritability, anorexia, constipation, chicken breasts, "
  • the active calcium that is popular in the market is a type of calcium oxide, which is prepared by using marine biological oysters and shells that have been calcined and pulverized at high temperature. It represents the highest level in the current calcium market and can be called the second generation calcium.
  • the first is that seawater is becoming increasingly polluted. Active calcium produced by this method will inevitably leave some heavy metal elements that are harmful to people's health in it.
  • the active calcium produced by a developed western country specifically states: Non-marine biological shell made of raw materials. Obviously, the ideal source of calcium still needs further research and development! The measurement proved that the bioavailability of various active calcium on the international market is less than 30%.
  • the second is the low calcium content of calcium on the market, only 10-55%.
  • additives are needed to make the calcium content of the commercially available calcium agent lower, which cannot meet the daily calcium intake required by the human body. Therefore, it is imperative to find a new and effective calcium agent which is easily absorbed by the human body. Summary of invention
  • One of the objects of the present invention is to provide an ultrafine particle size calcium oxide powder.
  • Another object of the present invention is to provide a calcium-containing composition which is easily absorbed by the human body.
  • Another object of the present invention is to provide a calcium-containing composition with high calcium content and high bioavailability.
  • an ultra-fine calcium oxide product has a fineness of less than 1 micron and an average fineness of 100 nm.
  • the invention also relates to a calcium-containing composition, which comprises an ultra-fine calcium oxide product with a fineness of 10 ′ 6 ⁇ 1 (T 9 m).
  • FIG. 1 is a schematic flow chart of preparing the ultrafine calcium oxide powder of the present invention by a plasma method
  • FIG. 2 is a particle size distribution curve diagram of the ultrafine calcium oxide powder in Example 1.
  • the inventor of the present application has been working for many years to find a calcium-containing composition that has a high calcium content and is easily absorbed by the human body.
  • the inventors found that reducing the particle size of calcium oxide to a certain range can increase the absorption of calcium by the human body and has high bioavailability.
  • an oxide ultrafine calcium powder the fineness of ⁇ ' ⁇ - io' 9 m , or at least a fineness of 10 '6 - 10' 9 m in diameter accounted for 90% or more, preferably fineness of about 10- 7 m or less, e.g., 10 '7 - 10' 8 m, or particle size of about 10-7-- 70% or more of particles of 10 '8 m in.
  • This ultra-fine calcium oxide powder is also referred to as nanometer calcium oxide in this specification because its fineness is on the order of nanometers.
  • a method for preparing the ultra-fine calcium oxide powder includes decomposing the calcium carbonate powder by a plasma method.
  • the equipment for generating the plasma is a commercially available equipment.
  • the calcium carbonate powder used in this method is readily available on the market. This calcium carbonate powder can be derived from marine organisms or it can be obtained from other sources.
  • raw calcium carbonate powder 1 is sent to a plasma reaction furnace 4 by a carrier gas 8.
  • the average particle size of the calcium carbonate powder used is about 100 mesh or less, and the carrier gas may be a pressurized gas such as air or an inert gas.
  • the use of pressurized gas as the carrier gas can help the raw materials move in the process, so the pressure of the carrier gas should be sufficient to maintain the flow state of the raw materials throughout the process.
  • the pressure of the carrier gas is 0.5 atmosphere or more.
  • the raw material 1 is in a plasma reaction furnace, and under the action of the energy provided by the plasma generator 3, the plasma 2 is decomposed to generate ultrafine particles of calcium oxide powder and carbon dioxide gas.
  • the reaction temperature in the plasma reactor is controlled at 2000 e C or above.
  • the reaction product was collected in one stage 5 to obtain ultrafine particles of calcium oxide powder.
  • Superfine particles of calcium oxide powder can be set for secondary collection6.
  • the carbon dioxide gas is discharged through the exhaust gas filtering system 7.
  • the product can be collected by cooling cyclones, cloth bags and other common facilities.
  • a product obtained by decomposing calcium carbonate by a plasma method has a particle size of about 10 ' 6 -10', or at least 90% of the particles have a particle size of 10 ' 6 -10' 9 m.
  • Preferred particle size of about 10 ⁇ 3 ⁇ 4 or more, e.g. 10 ⁇ 7 _10 ⁇ 3 ⁇ 4 or at least 70% --80% of the particle size is 10 * or more, e.g., 10 "7 -10'm o calcium oxide content in the product of about 90 % or more, preferably 95% or more.
  • the ultra-fine calcium oxide powder of the present invention is easily absorbed by the human body, and its bioavailability can be as high as 40%. Therefore, the ultra-fine calcium oxide powder of the present invention can be used as a source of human or animal calcium, or used to supplement human or animal calcium alone or with other substances, and can be used as a component to be incorporated into other products, such as food. , Feed, nutrition or medicine, etc., can also be made into separate products to provide calcium to animals or humans.
  • a calcium-containing composition comprising a particle size of 10 ⁇ 6 - 10 Oxidation of calcium powder, and one or more physiologically acceptable excipients and / or adjuvants, preferably a particle size of 10 '7--10 '3 ⁇ 41 of calcium oxide.
  • the calcium-containing composition contains other ultrafine calcium oxide of the present invention.
  • the calcium oxide of the present invention should be contained in the composition in an amount sufficient to meet human and / or animal needs for calcium.
  • trace elements useful for humans and / or animals can also be added to the composition, such as magnesium, selenium, strontium, fluorine, thallium or zinc, and the like.
  • the excipient may be a conventional excipient, such as citric acid, malic acid, starch, etc., and other nutritional ingredients or other components may also be added.
  • a calcium-containing composition of the present invention has the following formula (parts by weight): nano-calcium oxide 70-80
  • Trace elements 0.5-1 The trace elements in this formulation can be selected from one of magnesium, selenium, strontium, fluorine, iron or zinc or a mixture thereof. Bioactive animal bone density bioavailability test
  • the results were shown in Table 1, and DPX-L from LUNAR was used. Dual energy; I: line bone density tester, measure its bone density (BMD), the results are shown in Table 2.
  • the first group increased by 0.035g / cm 2 on average
  • the second group increased by 0.027g / cm 2 on average
  • the third group increased by 0.014g / cm 2 on average, which proves that the new type of nano calcium is easy for animals Absorbed by bones, bioavailability is 25% higher than calcium carbonate.
  • Experimental weight change (g) of calcium oxide, calcium carbonate of the present invention and control rats (group) Group number Initial week, week, week, week, week, week, week, week, week, week, week, week, week
  • Sample sample name sample weight g 'measured radioactivity unit weight radioactivity, count / 100S degrees, count / 100s «g
  • Sample sample name sample weight g 'measured radioactivity unit weight radioactivity, count / 1Q0S degrees, count / lQGs, g
  • the raw materials and operation procedures were the same as in Example 1, but the reaction temperature was controlled at 3000 e C, and the average particle size of the obtained product was less than 10 ⁇ .
  • Example 3 70 kg of calcium oxide having a purity of 99.5% and an average particle diameter of 75 nanometers was added to a universal 120 liter mixer, and then 4 kg of citric acid, 4 kg of malic acid, and starch were added. 3 kilograms, 3 kilograms of sugar, 100 grams of strontium, 165 grams of fluorine, 150 grams of iron, and 170 grams of zinc were fully mixed and compressed into tablets in a general tablet machine, and the tablet weight was 0.5 grams, for a total of 165,000 tablets. The calcium-containing composition of the present invention is obtained.
  • Example 4 except that the formula was changed to 80 kg of calcium oxide, 6 kg of citric acid, 6 kg of malic acid, 5 kg of starch, 5 kg of sugar and 120 g of strontium, 500 g of fluorine, 180 g of iron, and 130 g of zinc The remaining conditions were the same as in Example 3 to prepare the calcium-containing composition of the present invention.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Geology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Composite Materials (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • General Physics & Mathematics (AREA)
  • Materials Engineering (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Thermal Sciences (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Oxyde de calcium pulvérulent ultrafin dont les particules ont une grosseur comprise entre 10?-6 et 10-9¿ m. Cet oxyde est fabriqué par décomposition par plasma à partir d'un carbonate de calcium. On a également prévu une composition renfermant du calcium et comportant ledit oxyde de calcium pulvérulent ultrafin. Cette composition est utilisable dans l'administration à l'homme et aux animaux du calcium nécessaire.
PCT/CN1994/000097 1993-12-03 1994-12-03 Oxyde de calcium pulverulent ultrafin, sa preparation et son utilisation Ceased WO1995015293A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU11048/95A AU1104895A (en) 1993-12-03 1994-12-03 An ultra fine powder calcium oxide, preparation and use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN93114932.0 1993-12-03
CN 93114932 CN1091007A (zh) 1993-12-03 1993-12-03 高营养、高疗效、易吸收的新型钙剂——纳米钙(钙王)

Publications (1)

Publication Number Publication Date
WO1995015293A1 true WO1995015293A1 (fr) 1995-06-08

Family

ID=4990710

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN1994/000097 Ceased WO1995015293A1 (fr) 1993-12-03 1994-12-03 Oxyde de calcium pulverulent ultrafin, sa preparation et son utilisation

Country Status (3)

Country Link
CN (1) CN1091007A (fr)
AU (1) AU1104895A (fr)
WO (1) WO1995015293A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014075197A1 (fr) 2012-11-15 2014-05-22 Kalkfabrik Netstal Ag Oxyde de calcium modifié en surface
EP2944610A1 (fr) 2014-05-14 2015-11-18 Kalkfabrik Netstal AG Moulage par stratification de poudres riches en oxyde de calcium et dispositif et procédé de préparation de poudres riches en oxyde de calcium

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1060336C (zh) * 1995-12-05 2001-01-10 孔彦平 一种防治钙质缺损的药物及其制备方法
CN102461897B (zh) * 2010-11-05 2013-11-13 威海紫光生物科技开发有限公司 复合纳米钙粉及制作方法
CN110934306A (zh) * 2019-12-05 2020-03-31 广东贝尤安新材料科技有限公司 一种基于贝壳的离子钙型补钙剂

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0226810A (ja) * 1988-07-14 1990-01-29 Kazuo Sugiyama 金属酸化物の製造法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0226810A (ja) * 1988-07-14 1990-01-29 Kazuo Sugiyama 金属酸化物の製造法

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014075197A1 (fr) 2012-11-15 2014-05-22 Kalkfabrik Netstal Ag Oxyde de calcium modifié en surface
US9611175B2 (en) 2012-11-15 2017-04-04 Kalkfabrik Nestal AG Surface-modified calcium oxide
US10457811B2 (en) 2012-11-15 2019-10-29 Kalkfabrik Netstal Ag Surface-modified calcium oxide
EP2944610A1 (fr) 2014-05-14 2015-11-18 Kalkfabrik Netstal AG Moulage par stratification de poudres riches en oxyde de calcium et dispositif et procédé de préparation de poudres riches en oxyde de calcium

Also Published As

Publication number Publication date
CN1091007A (zh) 1994-08-24
AU1104895A (en) 1995-06-19

Similar Documents

Publication Publication Date Title
JP7280318B2 (ja) 炭酸ランタン水酸化物、ランタンオキシカルボネートならびにその製造および使用方法
CN100543427C (zh) 碳酸钙颗粒
CA1281289C (fr) Preparation ultradense, plus soluble et plus biodisponible, de citrate de calcium
CN103961368B (zh) 蒙脱石负载的氢氧化钙抗酸剂
EP2380850A1 (fr) Montmorillonite de sodium modifiée, procédé d'élaboration et utilisations correspondants
JPH08208490A (ja) 改良されたカルシウム食事補助組成物
WO2007090355A1 (fr) Procédé de purification de montmorillonite, montmorillonite purifiée et sa composition
CN107929313B (zh) 用于预防和治疗钙缺乏症的天然型牡蛎碳酸钙制剂及其制备方法
MX2011002847A (es) Polvo de compuesto organico combinado para uso medico y metodo de produccion y suspension del mismo.
CN1209322A (zh) 新型高效中性补钙剂系列新产品
WO1995015293A1 (fr) Oxyde de calcium pulverulent ultrafin, sa preparation et son utilisation
WO2016100826A1 (fr) Formulations de complexe minéral pour administration par voie orale et procédés d'utilisation associés
CN116138459B (zh) 一种易分散、易吸收钙粉剂组合物及其制备方法
EP1242067B1 (fr) Formate de calcium comme complement alimentaire
JP2020007300A (ja) うつ病又はうつ状態の予防又は治療剤
JP7461006B2 (ja) 関節炎の予防又は治療剤
KR20090007226A (ko) 칼슘을 함유하는 나노입자 및 그 제조방법
CN101268836B (zh) 一种营养高钙冲剂及其生产制作工艺
CN112715952A (zh) 多维钙自乳化组合物及其制剂的制备方法
JP2020079228A (ja) 二日酔いの予防又は治療剤
CN102000110A (zh) 一种用于预防或治疗骨和关节疾病的组合物及其制备方法
CN112791101B (zh) 一种多种维生素矿物质片剂及其制备方法
CN1823764A (zh) 一种含有雷奈酸锶和维生素d药物组合物
CN1137381A (zh) 超微钙营养剂
Lippmann et al. A comparison of three types of lithium release preparations

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW NL NO NZ PL PT RO RU SD SE SI SK TJ TT UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE MW SD SZ AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA